Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation?

Murakawa, Y; Yamashita, T; Kanese, Y; Omata, M

Murakawa, Y; Yamashita, T; Kanese, Y; Omata, M.

Affiliation

Murakawa Y; Second Department of Internal Medicine, University of Tokyo, Japan.

J Am Coll Cardiol ; 29(3): 688-92, 1997 Mar 01.

Article in En | MEDLINE | ID: mdl-9060912

Subject(s)

Anti-Arrhythmia Agents/pharmacology; Electric Countershock; Heart/drug effects; Pyrimidinones/pharmacology; Ventricular Fibrillation/therapy; Action Potentials; Animals; Anti-Arrhythmia Agents/therapeutic use; Dogs; Pyrimidinones/therapeutic use; Treatment Outcome; Ventricular Fibrillation/drug therapy

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidinones / Ventricular Fibrillation / Electric Countershock / Heart / Anti-Arrhythmia Agents Limits: Animals Language: En Journal: J Am Coll Cardiol Year: 1997 Document type: Article Affiliation country: Japan Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links